Easy opening device for a medicament storage carton

Abstract

A carton for medicament storage includes a bottom carton and a lid. The bottom carton includes a bottom wall, a first side wall, a second side wall, a back wall, and a front wall. The carton also includes a lid coupled to the bottom carton and movable between an open position and a closed position. When the lid is in the closed position, the bottom carton is enclosed by the lid. Additionally, the carton includes a release tab including a portion of one of the lid and the second front wall and defined by a perforation line in the one of the lid and the bottom carton. The carton can also include an adhesive positioned on at least a portion of the release tab and selectively coupling the lid to the bottom carton. When the carton is in the closed position, the release tab is secured to the one of the lid and the bottom carton via the perforation and to the other of the lid and the bottom carton via the adhesive. Alternatively, when the lid is in the open position, the release tab is separated from the one of the lid and the bottom carton along the perforation line and secured to the other of the lid and the bottom carton via the adhesive.

Description

[0001] Cross-references to related applications

[0002] This application claims priority to U.S. Patent Application No. 63 / 073,800, filed September 2, 2020, which is incorporated herein by reference. Technical Field

[0003] This disclosure relates to pharmaceutical storage boxes, and more particularly to storage boxes. Background Technology

[0004] Many medicine storage boxes are used to store individual medications for home use. These boxes are typically made to hold one, two, three, four, or more doses. The boxes used to store individual doses need to be sealed to prevent tampering with the contents before first personal use. Therefore, most medicine storage boxes are sealed with tamper-proof seals such as tamper-proof tags; if the tamper-proof tag is removed, the box will be damaged.

[0005] Pharmaceutical storage containers with tamper-proof seals may be difficult to open without using cutting tools or damaging the packaging. Using cutting tools can be dangerous, and in some cases, damage to the carton can expose the stored medications to the external environment. These pharmaceutical storage cartons may be more secure and come with tamper-proof certification, but may still be difficult to open. Summary of the Invention

[0006] This disclosure relates to a cardboard box for storing pharmaceuticals. The cardboard box includes a bottom box body having a bottom wall, a first side wall, a second side wall, a rear wall, and a front wall. The cardboard box also includes a lid hinged to the rear wall. Between an open position and a closed position, the lid includes a third side wall adjacent to the first side wall, a fourth side wall adjacent to the second side wall, and a second front wall adjacent to the first front wall. Additionally, when the lid is in the closed position, the bottom box body is disposed within the third side wall, the fourth side wall, and the second front wall. The cardboard box also includes a release tab that includes a portion of the second front wall and is defined between the bottom edge of the second front wall and a perforation line in the second front wall. Furthermore, when the lid is in the open and closed positions, the release tab is secured to the bottom box body. Additionally, when the lid is in the open position, the release tab separates from the second front wall along the perforation line.

[0007] This disclosure relates to a cardboard box for storing pharmaceuticals. The cardboard box includes a bottom box body having a bottom wall, a first side wall, a second side wall, a rear wall, and a front wall. The cardboard box also includes a lid hinged to the rear wall. Between an open position and a closed position, the lid includes a third side wall adjacent to the first side wall, a fourth side wall adjacent to the second side wall, and a second front wall adjacent to the first front wall. Additionally, when the lid is in the closed position, the bottom box body is disposed within the third side wall, the fourth side wall, and the second front wall. The cardboard box also includes a release tab that includes a portion of the second front wall and is defined between the bottom edge of the second front wall and a perforation line in the second front wall. Furthermore, when the lid is in the open and closed positions, the release tab is secured to the bottom box body via an adhesive label. Additionally, when the lid is in the open position, the release tab separates from the second front wall along the perforation line. Attached Figure Description

[0008] This disclosure is believed to be more fully understood from the following description taken in conjunction with the accompanying drawings. To illustrate other elements more clearly, some drawings may be simplified by omitting selected elements. In some drawings, the omission of these elements does not necessarily indicate the presence or absence of a particular element in any exemplary embodiment, unless it can be clearly indicated in the corresponding written description. Furthermore, not all drawings need to be drawn to scale.

[0009] Figure 1 It is a plan view of a punched part of a medicine storage carton including an easy-open push-button feature.

[0010] Figure 2 It includes Figure 1 A three-dimensional view of a medicine storage box with easy-to-open features.

[0011] Figure 3 It is a plan view including an easy-open feature of a release tab, which constitutes a push-open feature.

[0012] Figure 4 yes Figure 2 A perspective view of a medicine storage box, which additionally includes a sealing label for sealing the medicine storage box.

[0013] Figure 5 It is pressing Figure 2 A three-dimensional diagram of the easy-open features of a medicine storage box.

[0014] Figure 6 yes Figure 2 A perspective view of a medicine storage box, the easy-open feature of which allows it to be removed from the outer front wall.

[0015] Figure 7It is a plan view of a die-cut pharmaceutical storage box featuring an easy-to-open push-pull design.

[0016] Figure 8 It includes Figure 7 A three-dimensional view of a medicine storage box with easy-to-open features.

[0017] Figure 9 It includes the release of lamellae. Figure 7 The plan view of the easy-open feature, the release tab constitutes a push-pull opening feature.

[0018] Figure 10 yes Figure 7 A perspective view of a medicine storage box, which additionally includes a sealing label for sealing the medicine storage box.

[0019] Figure 11 It is pressing Figure 7 A three-dimensional diagram of the easy-open, push-pull design of the medicine storage box.

[0020] Figure 12 yes Figure 8 A perspective view of a medicine storage box, the easy-open feature of which allows it to be removed from the outer front wall.

[0021] Figure 13 It is a plan view of a die-cut part of an alternative medicine storage box with an easy-open push-button feature.

[0022] Figure 14 It features an easy-open push-button design. Figure 13 A three-dimensional diagram of an alternative medicine storage box.

[0023] Those skilled in the art will understand that the elements in the figures are shown for simplicity and clarity and are not necessarily drawn to scale. For example, the size and / or relative position of some elements in the figures may be enlarged relative to other elements to aid in understanding the various embodiments of the invention. Furthermore, commonly used but easily understood elements that are available or necessary in commercially viable embodiments are generally not drawn to facilitate viewing these various embodiments with less obstruction. It will also be understood that certain actions and / or steps may be described or depicted in a specific sequence of occurrence, and those skilled in the art will understand that such specificity in sequence is not actually necessary. It will also be understood that the terms and expressions used herein have the ordinary technical meaning consistent with those of skill in the art as set forth above, except for the different specific meanings set forth herein. Detailed Implementation

[0024] Medicine storage cartons store and protect various medications intended for household use. One such medicine storage carton includes a carton with a lid. The carton with a lid can include, for example, a covered carton (i.e., a carton with a cover) or a bottom-lid carton (i.e., a carton with a bottom lid). Such a carton can include a bottom box body hinged to the lid, the lid having side walls and a front wall that overlap with the side walls and front wall of the bottom box body. These cartons are used to protect the medications during transport and also ensure that the medications cannot be tampered with. The reason these cartons are ensured to be tamper-proof is that they are sealed with tamper-proof seals. Therefore, a carton with a broken seal or external damage can indicate that the contents of the carton have been tampered with and that the use of the medication may be unsafe. However, while the security provided by the tamper-proof seal is important, it makes opening the medicine storage carton difficult.

[0025] The easy-open device of the medicine storage box disclosed herein provides enhanced security while also making the medicine storage container user-friendly and highly convenient to use. For example, instead of tearing open the box to access the medicine or using a sharp cutting tool to cut open the tamper-evident seals, the box can include easy-open features that maintain the integrity of all tamper-evident seals during transport and storage while allowing the medicine storage box to be easily opened.

[0026] The device disclosed herein includes a release tab disposed on the front wall of the lid. This release tab can be removed from the front wall, allowing the tamper-evident closure label attached to both the release tab and the bottom of the storage tray to separate from the front wall of the lid, thus enabling the opening of the medication storage tray. Therefore, the user can remove the release tab from the front wall of the lid without cutting the closure label or disassembling the storage tray. Additionally, the storage tray of this disclosure includes tabs disposed on the bottom body of the storage tray, which allow the storage tray to be selectively closed after the closure label has been removed from the lid.

[0027] The device disclosed herein can be incorporated into any carton style or design. Such carton designs include, but are not limited to: exposed cartons that are slidably received within and enclosed by a carton sleeve, cartons with removable tops, sealable cylinders, etc. For example, the device disclosed herein may include one or more release tabs on a pharmaceutical storage carton. For instance, instead of a carton with a hingedly attached lid, a pharmaceutical storage carton may include a bottom carton and a top carton separate from the bottom carton. In such an example, the top carton may include a first release tab and a second release tab, as well as a closing label for each release tab. Thus, a user can remove each of the first and second release tabs from the top carton. Accordingly, the release tabs can be incorporated into any carton style or design.

[0028] Figure 1 This is a plan view of the die-cut part 100 of a medicine storage carton 102 including the easy-open feature 104. The carton 102 is made of a single material. For example, the carton 102 may be made of cardboard, corrugated cardboard, cardboard, or similar materials. However, the carton 102 may be made of several pieces glued together or otherwise fixed together. The carton 102 includes a plurality of fold lines 106 that divide the carton 102 into multiple walls and flaps. When each of the plurality of fold lines 106 is folded in, the carton 102 forms a box-shaped carton.

[0029] Carton 102 includes a bottom box body 110 having a bottom wall 112, a first side wall 114, a second side wall 116, a rear wall 118, and a first front wall 120. The rear wall includes flaps 122a and 122b, and the first front wall 120 includes flaps 124a and 124b. When each of the first side wall 114, the second side wall 116, the rear wall 118, and the first front wall 120 is folded upwards, flaps 122a and 124a are glued to the first side wall 114, while flaps 122b and 124b are glued to the second side wall 116. Alternatively, flaps 122a, 122b, 124a, and 124b may be secured to the first side wall 114 and the second side wall 116 via interlocking slots, other adhesives, or other known carton and box assembly methods. Therefore, the first side wall 114, the second side wall 116, the rear wall 118 and the first front wall 120 are all fixed together to form the bottom box 110.

[0030] Additionally, the first anterior wall 120 includes a first tab 126a and a second tab 126b. Additionally, the first anterior wall 120 includes a material reduction section 128. The material reduction section 128 increases the flexibility of the first anterior wall 120 compared to a first anterior wall 120 without the material reduction section 128.

[0031] Furthermore, carton 102 includes a lid 140 hinged to a rear wall 118. In this version, lid 140 is a cover and includes a top wall 142, a third side wall 144, a fourth side wall 146, and a second front wall 148. The third side wall 144 includes a flap 152a, and the fourth side wall includes a flap 152b. When the third side wall 144, the fourth side wall 146, and the second front wall 148 are folded, flaps 152a and 152b are glued to the second front wall 148. Flaps 152a and 152b can be secured to the first side wall 114 and the second side wall 116 via interlocking slots, other adhesives, or other known carton and box assembly methods. Therefore, when the third sidewall 144, the fourth sidewall 146, and the second front wall 148 of the cover 140 are assembled, the cover covers the bottom box 110 including the first sidewall 114, the second sidewall 116, and the first front wall 120.

[0032] The second front wall 148 includes a perforated line 160 surrounding a release tab 162 adjacent to a bottom edge 164 of the second front wall 148. The release tab 162 is enclosed by the perforated line 160 and the bottom edge 164. Figure 1 As shown, the release tab 162 includes a first slit-shaped cut 166, and the bottom wall 112 includes a second slit-shaped cut 168. A perforated line 160 allows the release tab 162 to be detached from the second front wall 148 when sufficient force is applied. Figure 1 As shown, the release tab 162 is a partially rectangular shape with rounded edges; however, the release tab 162 can be any shape of various shapes (including semicircles, triangles, quadrilaterals, pentagons, etc.).

[0033] In some examples, when flaps 152a and 152b are glued to the second front wall 148, the second front wall 148 may include latching features 154a and 154b. When the carton 102 is assembled, tab holder 154a receives tab 126a, and tab holder 154b receives tab 126b. Thus, tab 126a rests on tab holder 154a to provide resistance to opening the carton 102. Additionally, when the carton 102 is closed, tab 126a moves together with tab holder 154a to the appropriate position, producing an audible click that indicates the carton is closed. Although Figure 1 The cardboard box 102 is shown as having two tabs, 126a and 126b, but the cardboard box 102 may include more or fewer than two tabs.

[0034] Figure 2 It includes storage cavity 210 and Figure 1 A perspective view of the medicine storage box 202 with easy-open feature 104. (See image below.) Figure 2 As shown, the paper box 202 is based on... Figure 1 The punched part 100 shown is folded and assembled such that the storage cavity 210 can receive and store the drug delivery device 212 containing the drug. Accordingly, the bottom housing 110 is disposed within the cover 140. Therefore, the first sidewall 114 is adjacent to the third sidewall 144, and the second sidewall 116 is adjacent to the fourth sidewall 146. Additionally, as... Figure 2 As shown, the second front wall 148 is the outer front wall, and the bottom edge 164 of the outer front wall is adjacent to the bottom wall 112.

[0035] According to this disclosure, the cartridge 202 is designed to store at least one drug delivery device 212 in a storage cavity 210 disposed in the bottom housing 110. While the cartridge 202 is shown as having one drug delivery device 212, in other examples, the cartridge 202 may store one, two, or more drug delivery devices. The drug delivery device 212 may be a pre-filled hypodermic syringe or a pre-filled autoinjector product for use with an autoinjector.

[0036] Additionally, the bottom housing 110 includes tabs 126a and 126b disposed on the first front wall 120. Tab 126a is hingedly connected to a flap 152a of the third side wall 144, and tab 126b is hingedly connected to a flap 152b of the fourth side wall 146. Thus, when tabs 126a and 126b engage with latching features 154a and 154b (such as flaps 152a and 152b), respectively, the carton 202 can be secured in a closed position.

[0037] Figure 3 This is a plan view of an easy-open feature 104 including a release tab 162, which constitutes the easy-open feature 104. The release tab 162 is partially demarcated by a perforation line 160. The perforation line 160 consists of a series of cuts 302. Figure 3 The length of the cut portion 302 shown can be longer or shorter. Additionally, although five cut portions 302 are shown, the perforation line can consist of more or fewer cut portions 302. Additionally, the release tab 162 includes a first kiss-shaped cut portion 166. The first kiss-shaped cut portion 166 is a partial cut portion that passes through the release tab 162. The partial cut portion improves the adhesion between the release tab 162 and the tamper-evident seal by increasing the surface area on which the tamper-evident seal can adhere. Although the first kiss-shaped cut portion 166 is triangularly wave-shaped, the first kiss-shaped cut portion 166 can be any shape or pattern of various forms or patterns.

[0038] Figure 4 yes Figure 2 A perspective view of a medicine storage box 202, which additionally includes a sealing label 402 for sealing the medicine storage box 202. The sealing label 402 acts as an tamper-evident seal. Any attempt to tear the sealing label 402 off the box 202 will cause visible damage to the box 202 and / or the sealing label 402. Accordingly, a person can avoid using medicine stored in a box that may have been tampered with by noticing evidence of such tampering.

[0039] like Figure 4As shown, the release tab 162 is secured to the bottom wall 118 via a closure tag 402. Because the release tab 162 is connected to the second front wall 148, the cover 140 is secured in a closed state. Alternatively, the release tab 162 is secured to the first front wall 120 of the bottom housing 110 via an adhesive provided between the release tab 162 and the first front wall 120. However, in both examples, the cover 140 is secured in a closed state by the closure tag 402 or by an adhesive applied to the cover 140 only within the area of ​​the release tab 162. Additionally, the adhesive or closure tag 402 may be applied to a considerable portion of the release tab 162, including along or adjacent to the perforation line 160 of the release tab 162. For example, the adhesive or closure tag 402 may have a similar shape and size to the release tab 162. In such an example, the adhesive or closure tag 402 concentrates the force applied to the release tab 162 on the perforation line 160. Accordingly, the adhesive or closure label 402, which essentially covers the entire release tab, makes it easier to remove the release tab 162 from the second front wall 148.

[0040] Furthermore, a sealing label 402 is disposed above the first kiss-shaped cut portion 166 and the second kiss-shaped cut portion 168. Therefore, the sealing label 402 has a strong adhesive bond to both the release tab 162 and the bottom wall 112. Consequently, tampering with the sealing label 402 will result in noticeable tampering and / or damage. Therefore, the sealing label 402 provides security regarding the integrity of the medication stored in the carton 202.

[0041] although Figure 4 Not shown, but in some examples, the carton 202 includes a first outer finish with a first texture, and the release tab 162 includes a second outer finish with a second texture. The first texture differs from the second texture, allowing the user to perceive the approximate positioning of the release tab 162 and the closure label 402. Therefore, the difference between the first and second textures improves the ease of use and usability of the storage carton 202. In some examples, the first texture may be a wax or varnish protecting information printed on the outer surface of the carton 202. In contrast, the second texture may be less treated to improve adhesion between the closure label 402 and the carton 202, thereby enhancing the security of the tamper-evident seal.

[0042] Figure 5 It is pressing Figure 2 A perspective view of the easy-open feature 104 of the medicine storage box. (See diagram 104.) Figure 5 As shown, a user can hold the cardboard box 202 with one hand while pressing the easy-open feature 104. However, the cardboard box 202 may be too large to be opened with one hand, so it may be necessary to hold the cardboard box 202 with one hand while pressing the easy-open feature 104 with the other hand.

[0043] According to this disclosure, the release tab 162 is an opening feature 104 of the carton that removes the release tab 162 from the second front wall 148. The release tab 162 also acts as a push tab that removes the release tab 162 from the second front wall 148. Because the closure label 402 adheres only to the bottom wall 112 and the release tab 162, the second front wall 148 is no longer held in a closed position by the closure label 402.

[0044] For reference Figure 1 The first front wall 120 discussed includes a cut section 128. The cut increases the flexibility of the first front wall 120 relative to the second front wall 148. This increased flexibility of the first front wall 120 increases the distance the release tab 162 can travel. Because of the increased flexibility of the first front wall 120, the release tab 162 can travel further and is more easily detached from the second front wall 148. Furthermore, although the first front wall 120 has the cut section 128, when the carton 202 is closed, the material of the first front wall 120 should be higher than the release tab 162, so that the internal environment of the carton 202 remains separated from the external environment of the carton 202.

[0045] Figure 6 yes Figure 2 A perspective view of a medicine storage box 202, wherein the easy-open feature 104 of the medicine storage box is detached from the second front wall 148. With the release tab 162 detached from the second front wall 148, the cover 140 can be either opened or closed. In the open position, the cover 140 does not cover the bottom box body 110. In contrast, when in the closed position, the cover 140 covers the bottom box body 110. Additionally, in the closed position, tabs 126a and 126b engage latching features 154a and 154b (e.g., flaps 152a and 152b) to removably secure the cover 140 in the closed position.

[0046] Figure 7 This is a plan view of a die-cut piece 700 of a medicine storage carton 702, including an easy-open push-pull feature 704. The carton 702 is made of a single material. For example, the carton 702 may be made of cardboard, corrugated cardboard, cardboard, or similar materials. Additionally, the carton 702 includes a plurality of fold lines 706 that divide the carton 702 into multiple walls and flaps. When each of the plurality of fold lines 706 is folded in, the carton 702 forms a box-shaped carton.

[0047] The carton 702 includes a bottom box body 710 having a bottom wall 712, a first side wall 714, a second side wall 716, a rear wall 718, and a first front wall 720. The rear wall includes flaps 722a and 722b, and the first front wall 720 includes flaps 724a and 724b. When each of the first side wall 714, the second side wall 716, the rear wall 718, and the first front wall 720 is folded upwards, flaps 722a and 724a are glued to the first side wall 714, while flaps 722b and 724b are glued to the second side wall 716. Alternatively, flaps 722a, 722b, 724a, and 724b may be secured to the first side wall 714 and the second side wall 716 via interlocking slots, other adhesives, or other known box and carton assembly methods. Therefore, the first side wall 714, the second side wall 716, the rear wall 718 and the first front wall 720 are all fixed together to form the bottom box 710.

[0048] Additionally, the first anterior wall 720 includes a first tab 726a and a second tab 726b. The first anterior wall 720 also includes a material reduction section 728. The material reduction section 728 increases the flexibility of the first anterior wall 720 compared to the first anterior wall 720 without the material reduction section 728.

[0049] Furthermore, the carton 702 includes a lid 740 hinged to a rear wall 718. In this version, the lid 740 is a cover and includes a top wall 742, a third side wall 744, a fourth side wall 746, and a second front wall 748. The third side wall 744 includes a flap 752a, and the fourth side wall includes a flap 752b. When the third side wall 744, the fourth side wall 746, and the second front wall 748 are folded, flaps 752a and 752b are glued to the second front wall 748. Flaps 752a and 752b may be secured to the first side wall 714 and the second side wall 716 via interlocking slots, other adhesives, or other known carton and box assembly methods. In some examples, when flaps 752a and 752b are glued to the second front wall 748, the second front wall 748 may include latching features 754a and 754b. Therefore, when the third sidewall 744, the fourth sidewall 746 and the second front wall 748 of the cover 740 are assembled, the cover covers the bottom box 710 including the first sidewall 714, the second sidewall 716 and the first front wall 720.

[0050] The second front wall 748 includes a perforated line 760 surrounding a release tab 762 adjacent to its bottom edge 764. The release tab 762 is enclosed by the perforated line 760 and the bottom edge 764. The release tab 762 includes a pushing tab 770 and a tearing tab 772. The pushing tab 770 and the tearing tab 772 are separated by a fold line 774. Therefore, the pushing tab 770 is hingedly connected to the tearing tab 772. Figure 7 As shown, the release tab 762 also includes a snout-shaped cutting section 780.

[0051] In some examples, when flaps 752a and 752b are glued to the second front wall 748, the second front wall 748 may include latching features 754a and 754b. When the carton 702 is assembled, tab holder 754a receives tab 726a, and tab holder 754b receives tab 726b. Thus, tab 726a rests on tab holder 754a, providing resistance to opening the carton 702. Additionally, when the carton 702 is closed, tab 726a moves together with tab holder 754a to the appropriate position, producing an audible click, thereby indicating that the carton is closed. Although Figure 7 The cardboard box 702 is shown as having two tabs, 726a and 726b, but the cardboard box 702 may include more or fewer tabs.

[0052] Figure 8 It includes Figure 7 A perspective view of the medicine storage box 802 with easy-open feature 704. (See image below.) Figure 8 As shown, cardboard box 802 is made of, for example Figure 7 The cardboard box 702 is formed by folding the punched part 700 shown. (Example) Figure 8 As shown, the bottom housing 710 is disposed within the cover 740. Therefore, the first sidewall 714 is adjacent to the third sidewall 744, and the second sidewall 716 is adjacent to the fourth sidewall 746. Additionally, as... Figure 8 As shown, the second front wall 748 is the outer front wall, and the bottom edge 764 of the outer front wall is adjacent to the bottom wall 712.

[0053] According to this disclosure, the cartridge 802 is designed to store at least one drug delivery device 812 in a storage cavity 810 disposed in the bottom housing 710. While the cartridge 802 is shown as having one drug delivery device 812, in other examples, the cartridge 802 may store one, two, or more drug delivery devices. The drug delivery device 812 may be a pre-filled hypodermic syringe or a pre-filled autoinjector product for use with an autoinjector.

[0054] Additionally, the bottom housing 710 includes tabs 726a and 726b disposed on the first front wall 720. Tab 726a is hingedly connected to a flap 752a of the third side wall 744, and tab 726b is hingedly connected to a flap 752b of the fourth side wall 746. Therefore, when tabs 726a and 726b engage with latching features 752a and 752b respectively, the carton 802 can be secured in a closed position.

[0055] Figure 9 It includes the release plate 762. Figure 7A plan view of the easy-open feature 704, which is constituted by the release tab. The release tab 762 is partially demarcated by a perforation line 760. The perforation line 760 consists of a series of cuts 902. Figure 9 The length of the cut portion 902 shown can be longer or shorter. Additionally, although five cut portions 902 are shown, the perforation line can consist of more or fewer cut portions 302. Additionally, the release tab 762 includes a kiss-shaped cut portion 780. The kiss-shaped cut portion 780 is a partial cut portion that passes through the release tab 762. The partial cut portion improves the adhesion between the release tab 762 and the tamper-evident seal by increasing the surface area on which the tamper-evident seal can adhere. Although the kiss-shaped cut portion 766 is triangularly wave-shaped, the first kiss-shaped cut portion 166 can be any shape or pattern of various shapes or patterns.

[0056] Figure 10 yes Figure 7 A perspective view of a medicine storage box 802, which additionally includes a sealing label 1002 for sealing the medicine storage box 802. The sealing label 1002 acts as an tamper-evident seal. Any attempt to tear the sealing label 1002 off the box 802 will cause visible damage to the box 802. Accordingly, one can avoid using medicine stored in a box that may have been tampered with.

[0057] like Figure 10 As shown, the release tab 762 is secured to the bottom wall 718 via a closure tag 1002. Because the release tab 762 is connected to the second front wall 748, the cover 740 is secured in a closed state. Alternatively, the release tab 762 is secured to the first front wall 720 of the bottom housing 710 via an adhesive provided between the release tab 762 and the first front wall 720. However, in both examples, the cover 740 is secured in a closed state by the closure tag 1002 or by an adhesive applied to the cover 740 only within the area of ​​the release tab 762. Additionally, the adhesive or closure tag 1002 may be applied to a considerable portion of the release tab 762, including along or adjacent to the perforation line 760 of the release tab 762. For example, a portion of the adhesive or closure tag 1002 may have a similar shape and size to the release tab 762. In such an example, the adhesive or closure tag 1002 concentrates the force applied to the release tab 762 onto the perforation line 760. Accordingly, the adhesive or sealing label 1002, which substantially covers the entire release tab 762, makes it easier to remove the release tab 762 from the second front wall 748.

[0058] A sealing label 1002 is disposed on the kiss-shaped cutter 780. Therefore, the sealing label 1002 has a strong adhesive bond with the release tab 762. Consequently, removal of the sealing label 1002 will result in a noticeable tampering. Therefore, the sealing label 1002 provides security regarding the integrity of the medication stored in the carton 802.

[0059] although Figure 10 Not shown, but in some examples, the carton 802 includes a first outer finish with a first texture, and the release tab 762 includes a second outer finish with a second texture. The first texture differs from the second texture, allowing the user to perceive the approximate positioning of the release tab 762 and the sealing label 1002. Therefore, the difference between the first and second textures improves the ease of use and usability of the storage carton 802. In some examples, the first texture may be a wax or varnish protecting information printed on the outer surface of the carton 802. In contrast, the second texture may be less treated to improve adhesion between the sealing label 1002 and the carton 802, thereby enhancing the security of the tamper-evident seal.

[0060] Figure 11 It is an operation Figure 7 A three-dimensional diagram illustrating the push-pull easy-open feature of the medicine storage box. (Example) Figure 11 As shown, a user can hold the cardboard box 802 with one hand while pressing the easy-open feature 704. However, the cardboard box 802 may be too large to be opened with one hand, so it may be necessary to hold the cardboard box 802 with one hand while pressing the easy-open feature 704 with the other hand.

[0061] According to this disclosure, the release tab 762 is an opening feature 704 of the cardboard box that removes the release tab 762 from the second front wall 748. The release tab 762 includes a push tab 770 that removes a first portion of the release tab 762 from the second front wall 748. Thus, the user can fold the release tab 762 around the fold line 774 and then tear the tab 772 to completely remove the release tab 762 from the second wall 748. Because the sealing label 1002 adheres only to the bottom wall 712 and the release tab 762, the second front wall 748 is no longer held in a closed position by the sealing label 1002.

[0062] For reference Figure 7The first front wall 720 discussed includes a cut section 728, wherein the cut increases the flexibility of the first front wall relative to the second front wall. This increased flexibility of the first front wall 720 increases the distance the release tab 762 can travel. Because of the increased flexibility of the first front wall 720, the release tab 762 can travel further and is more easily detached from the second front wall 748. Furthermore, although the first front wall 720 has the cut section 728, when the carton 802 is closed, the material of the first front wall 720 should be higher than the release tab 762, so that the internal environment of the carton 802 remains separated from the external environment of the carton 802.

[0063] Figure 12 yes Figure 8 A perspective view of a medicine storage box 802, wherein the easy-open feature 704 is detached from the second front wall 748. With the release tab 762 detached from the second front wall 762, the cover 740 can be both opened and closed. In the open position, the cover 740 does not cover the bottom box body 710. In contrast, when in the closed position, the cover 740 covers the bottom box body 710. Additionally, in the closed position, tabs 726a and 726b engage latching features 754a and 754b (e.g., flaps 752a and 752b) to removably secure the cover 740 in the closed position.

[0064] Figure 13 This is a plan view of a die-cut piece 1300 of an alternative medicine storage carton 1302 including the easy-open feature 1304. The carton 1302 can be made from a single material (e.g., cardboard, corrugated cardboard, cardboard, or similar material). Additionally, the carton can be made from several pieces glued together or otherwise secured together. As shown, the die-cut piece 1300 includes a plurality of fold lines 1306 that divide the carton 1302 into multiple walls and flaps. When each of the plurality of fold lines 1306 is folded in, the carton 1302 forms a box-shaped carton.

[0065] The cardboard box 1302 includes a bottom wall 1312, a first side wall 1314, a second side wall 1316, a rear wall 1318, and a front wall 1320. The first side wall 1314 includes flaps 1322a and 1322b, and the second side wall 1316 includes flaps 1324a and 1324b. When each of the first side wall 1314, the second side wall 1316, the rear wall 1318, and the front wall 1320 is folded, flaps 1322b and 1324b are glued to the bottom wall 1312. Alternatively, flaps 1322b and 1324b may be secured to the bottom wall 1312 via interlocking slots, other adhesives, or other known box and cardboard assembly methods. Therefore, the first side wall 1314, the second side wall 1316, the rear wall 1318, and the first front wall 1320 are all fixed together to form the bottom box body 1330 of the cardboard box 1302. Figure 14 (as shown in the image).

[0066] Furthermore, the cardboard box 1302 includes a lid 1340, which is hinged to the rear wall 1318. (As...) Figure 13 The lid 1340 shown is a lower lid and includes a top wall 1342. The top wall 1342 includes a front lip 1346, which is hingedly connected to the top wall 1342. When the lid 1340 of the cardboard box 1302 is in the closed position (see...), the lid is positioned as follows: Figure 14 When the top wall 1342 is covered with flaps 1322a and 1322b, these two flaps fold inward (see also...). Figure 14 Additionally, in this configuration, the front lip 1346 of the cover 1340, after folding, is positioned behind and adjacent to the front wall 1320. The front wall 1320 also defines a release tab 1350, which is located at the top edge of the front wall. In this version, the release tab 1350 may be defined by a perforated line 1352 in the front wall 1320. The perforated line 1352 allows the release tab 1350 to be removed from the rest of the front wall 1320 under the application of sufficient force. Figure 13 As shown, the release tab 1350 is generally U-shaped (similar to the release tab depicted in the previous embodiment), and... Figure 1 Similar to the release tab 162, it has generally straight sides and a curved bottom. In some examples, the medicine storage carton may further include one or more kiss-shaped cuts 1354 (similar to kiss-shaped cuts 166, 168) to improve the adhesion of the adhesive used to close the carton 1302.

[0067] Figure 14 yes Figure 13A perspective view of an alternative medicine storage box 1302, in its fully assembled / constructed configuration with the lid 1340 in the closed position. As shown, the medicine storage box 1302 includes a bottom box body 1330 and a lid 1340 (shown as the lower lid). This means that the box 1302 ( Figure 14 (Seen in the closed position) includes a front lip 1346 disposed inside the bottom housing 1330 and behind the front wall 1320. The carton 1302 further includes a release tab 1350 defined by the front wall 1320. Finally, an adhesive (in this version, an adhesive label 1410) is applied over the corner where the lid 1340 meets the front wall 1320, with a portion of the label 1410 adhering to the release tab 1350 and the top wall 1342 of the lid 1340. Thus, when sufficient force is applied to the release tab 1350, the release tab 1350 separates from the front wall 1320, which allows the lid 1340 to move upward hingedly, thereby carrying the release tab 1350 and the label 1410 together with the lid to the open position. Accordingly, in the closed position, the adhesive label 1410 and the release tab 1350 keep the cover 1340 in the closed position, but after the release tab 1350 separates from the front wall 1320, the cover 1340 moves freely to its open position.

[0068] Additionally, in some examples, the adhesive or adhesive label 1410 may be applied to a substantial portion of the release tab 1410, including along or adjacent to the perforation line 1352 of the release tab 1350. For example, a portion of the adhesive or adhesive label 1410 may have a similar shape and size to the release tab 1410. In such examples, the adhesive or adhesive label 1410 concentrates the force applied to the release tab 1350 on the perforation line 1352. Accordingly, the adhesive or adhesive label 1410, which substantially covers the entire release tab 1350, makes it easier to remove the release tab 1350 from the front wall 1320.

[0069] The above description describes various devices, components, parts, subsystems, and methods used in connection with drug delivery devices. Devices, components, parts, subsystems, methods, or drug delivery devices may further include or be used with pharmaceutical agents, including but not limited to those identified below and their class and biosimilar counterparts. As used herein, the term pharmaceutical agent is used interchangeably with other similar terms and can be used to refer to any type of pharmaceutical agent or therapeutic material, including traditional and non-traditional pharmaceutical agents, nutritional supplements, tonics, biologics, bioactive agents and compositions, macromolecules, biosimilars, bioequivalents, therapeutic antibodies, peptides, proteins, small molecules, and class of substances. Non-therapeutic injectable materials are also included. Pharmaceutical agents may be in liquid form, lyophilized form, or in a form that can be reconstructed from a lyophilized form. The following exemplary list of pharmaceutical agents should not be considered as all-encompassing or restrictive.

[0070] The medication will be contained in a reservoir. In some cases, the reservoir is a master container that is filled or pre-filled with the medication for treatment. This master container can be a vial, cartridge, or pre-filled syringe.

[0071] In some embodiments, the reservoir of the drug delivery device may be filled with a colony-stimulating factor (such as granulocyte colony-stimulating factor (G-CSF)), or the device may be used in conjunction with a colony-stimulating factor. Such G-CSF agents include, but are not limited to, those mentioned above. (pegfilgrastim, filgastrim, PEGylated G-CSF, PEGylated hu-Met-G-CSF) and (Feigeril, G-CSF, hu-MetG-CSF) (Pefegstatin-cbqv) (LA-EP2006; Pfizer-bmez) or FULPHILA (Pfizer-bmez).

[0072] In other embodiments, the drug delivery device may include or be used with an erythropoiesis stimulant (ESA), which may be in liquid or lyophilized form. An ESA is any molecule that stimulates erythropoiesis. In some embodiments, the ESA is an erythropoiesis-stimulating protein. As used herein, "erythropoiesis-stimulating protein" means any protein that directly or indirectly causes activation of the erythropoietin receptor (e.g., by binding to the receptor and causing receptor dimerization). Erythropoiesis-stimulating proteins include: erythropoietin and its variants, analogs, or derivatives that bind to and activate the erythropoietin receptor; antibodies that bind to and activate the erythropoietin receptor; or peptides that bind to and activate the erythropoietin receptor. Erythropoiesis-stimulating proteins include, but are not limited to, erythropoietin. (epoetin α), (darbepoetin α), (Ibertinδ) (Methoxylated polyethylene glycol-Eberstein β) MRK-2578, INS-22 (Iberdinζ) (Ibertin β) (Iberdinζ) (Epstein-α), Epstein-α Hexal, (Ibertin α) (Ibertinθ) (Ibertinθ) (Ebertinθ), Ebertinα, Ebertinβ, Ebertinι, Ebertinω, Ebertinδ, Ebertinζ, Ebertinθ and Ebertinδ, PEGylated erythropoietin, carbamylated erythropoietin, and molecules or variants or analogs thereof.

[0073] The specific illustrative proteins are those described below, including their fusions, fragments, analogs, variants, or derivatives: OPGL-specific antibodies, peptides, related proteins, etc. (also known as RANKL-specific antibodies, peptides, etc.), including fully humanized OPGL-specific antibodies and human OPGL-specific antibodies, especially fully humanized monoclonal antibodies; myostatin-binding proteins, peptides, related proteins, etc., including myostatin-specific peptides; IL-4 receptor-specific antibodies, peptides, related proteins, etc., especially those that inhibit the activity mediated by the binding of IL-4 and / or IL-13 to the receptor; interleukin-1 receptor 1 (“IL1-R1”)-specific antibodies, peptides, related proteins, etc.; An G2-specific antibodies, peptides, and related proteins; NGF-specific antibodies, peptides, and related proteins; CD22-specific antibodies, peptides, and related proteins, especially human CD22-specific antibodies, such as, but not limited to, humanized and fully human antibodies, including but not limited to humanized and fully human monoclonal antibodies, particularly including but not limited to, human CD22-specific IgG antibodies, such as dimers like the human-mouse monoclonal hLL2γ-chain linked to the human-mouse monoclonal hLL2κ chain with a disulfide, for example, the human CD22-specific fully humanized antibody in epazuzumab, CAS registry number 501423-23-0; IGF-1 receptor-specific antibodies, peptides, and related proteins, etc. This includes, but is not limited to, anti-IGF-1R antibodies; B-7-related protein 1 specific antibodies, peptides, and related proteins (“B7RP-1”, also known as B7H2, ICOSL, B7h, and CD275), including but not limited to B7RP-specific fully human monoclonal IgG2 antibodies, including but not limited to fully human IgG2 monoclonal antibodies that bind to epitopes in the first immunoglobulin-like domain of B7RP-1, including but not limited to those that inhibit the interaction of B7RP-1 with its natural receptor ICOS on activated T cells; IL-15 specific antibodies, peptides, and related proteins, such as, in particular, humanized monoclonal antibodies, including but not limited to HuMaxIL-15 antibodies and related proteins, such as 145c7. IFNγ-specific antibodies, peptides, and related proteins, including but not limited to human IFNγ-specific antibodies, and including but not limited to fully human anti-IFNγ antibodies; TALL-1-specific antibodies, peptides, and related proteins, as well as other TALL-specific binding proteins; parathyroid hormone (“PTH”)-specific antibodies, peptides, and related proteins; thrombopoietin receptor (“TPO-R”)-specific antibodies, peptides, and related proteins; hepatocyte growth factor (“HGF”)-specific antibodies, peptides, and related proteins, including those targeting the HGF / SF:cMet axis (HGF / SF:c-Met), such as fully human monoclonal antibodies that neutralize hepatocyte growth factor / dispersant (HGF / SF);TRAIL-R2 specific antibodies, peptides, and related proteins; activin A specific antibodies, peptides, and proteins; TGF-β specific antibodies, peptides, and related proteins; amyloid-β protein specific antibodies, peptides, and related proteins; c-Kit specific antibodies, peptides, and related proteins, including but not limited to proteins binding to c-Kit and / or other stem cell factor receptors; OX40L specific antibodies, peptides, and related proteins, including but not limited to proteins binding to OX40L and / or other ligands of the OX40 receptor. (Alteplase, tPA); (Dabepoetin α) Erythropoietin [30-asparagine, 32-threonine, 87-valine, 88-asparagine, 90-threonine], Dabepoetin α, Novel Erythropoietin Stimulating Protein (NESP); (Eberferone α, or erythropoietin); GLP-1, (Interferon β-1a); (Tositumomab, an anti-CD22 monoclonal antibody); (Interferon-β); (alemtuzumab, anti-CD52 monoclonal antibody); (Ibertinδ); (bortezomib); MLN0002 (anti-α4β7 mAb); MLN1202 (anti-CCR2 chemokine receptor mAb); (etanercept, a TNF receptor / Fc fusion protein, a TNF blocker); (Ibertin α); (Cetuximab, anti-EGFR / HER1 / c-ErbB-1); (Growth hormone, human growth hormone); (Trastuzumab, an anti-HER2 / neu (erbB2) receptor mAb); Kanjinti TM (Trastuzumab-anns) anti-HER2 monoclonal antibody Biosimilars, or another product containing trastuzumab for the treatment of breast or gastric cancer; (Growth hormone, human growth hormone); (adalimumab); (panitumumab) (denosumab) (Dinosulimab), RANK ligand-based immunoglobulin G2 human monoclonal antibody (etanercept, TNF-receptor / Fc fusion protein, TNF blocker) (romiplostim), rilotumumab, ganitumab, conatumumab, brodalumab, insulin in solution; (interferon alfacon-1); (nesiritide; recombinant human B-type natriuretic peptide (hBNP)); (anakinra); (Shagstine, rhuGM-CSF); (Epazolizumab, anti-CD22mAb); Benlysta TM (lymphostat B, belimumab, anti-BlyS mAb); (Tennexase, t-PA analogue); (Methoxylated polyethylene glycol-Eberstein β); (Gitocilizumab ozomicin); (Efalizumab); (Certolizumab (CDP 870); Soliris) TM (eculizumab); pexelizumab (anti-C5 complement); (MEDI-524); (ranibizumab); (17-1A, edrecolomab); (lerdelimumab); TheraCim hR3 (nimotuzumab); Omnitarg (pertuzumab, 2C4); (IDM-1); (B43.13); (visilizumab); cantuzumab mertansine (huC242-DM1); (Ibertin β); (Orthoclone interleukin-11, human interleukin-11); (Muromonab-CD3, anti-CD3 monoclonal antibody); (Ibertin α); (infliximab, an anti-TNFα monoclonal antibody); (abciximab, anti-GP lIb / Ilia receptor monoclonal antibody); (Anti-IL6 receptor mAb); (Bevacizumab), HuMax-CD4 (zanolimumab); Mvasi TM (Bevacizumab-awwb); (Rituximab, anti-CD20 mAb); (Erlotinib); (Interferon α-2a); (basiliximab); (lumiracoxib); (palivizumab); 145c7-CHO (anti-IL15 antibody, see US Patent No. 7,153,507); (Naltaizumab, an anti-α4 integrin mAb); (MDX-1303, protective antigen mAb against B. anthrax); ABthrax TM ; (omalizumab); ETI211 (anti-MRSA mAb); IL-1 trap (extracellular domain of the Fc portion of human IgG1 and IL-1 receptor components (type I receptor and receptor accessory protein); VEGF trap (Ig domain of VEGFR1 fused to IgG1 Fc). (daclizumab); (Dalizumab, anti-IL-2RαmAb); (ibritumomabtiuxetan); (ezetimibe); (Atacicept (TACI-Ig); Anti-CD80 monoclonal antibody (galiximab); Anti-CD23 mAb (lumiliximab); BR2-Fc (huBR3 / huFc fusion protein, soluble BAFF antagonist); CNTO) 148 (golimumab, anti-TNFα mAb); HGS-ETR1 (mapatumumab, human anti-TRAIL receptor-1 mAb); HuMax-CD20 (ocrelizumab, anti-CD20 human mAb); HuMax-EGFR (zalutumumab); M200 (volociximab, anti-α5β1 integrin mAb); MDX-010 (iplimumab, anti-CTLA-4 mAb and VEGFR-1 (IMC-18F1); anti-BR3 mAb; anti-Clostridium difficile (C).(difficile) toxin A and toxin BC mAb MDX-066 (CDA-1 and MDX-1388); anti-CD22 dsFv-PE38 conjugates (CAT-3888 and CAT-8015); anti-CD25 mAb (HuMax-TAC); anti-CD3 mAb (NI-0401); adecatumumab; anti-CD30 mAb (MDX-060); MDX-1333 (anti-IFNAR); anti-CD38 mAb (HuMax CD38); anti-CD40L mAb; anti-Cripto mAb; anti-CTGF fibrinogen for stage I idiopathic pulmonary fibrosis (FG-3019); anti-CTLA4 mAb; anti-eosinophil chemokine 1 mAb (CAT-213); anti-FGF8 mAb; anti-ganglioside GD2 mAb; anti-ganglioside GM2 mAb; Anti-GDF-8 human mAb (MYO-029); Anti-GM-CSF receptor mAb (CAM-3001); Anti-HepC mAb (HuMax HepC); Anti-IFNα mAb (MEDI-545, MDX-198); Anti-IGF1R mAb; Anti-IGF-1R mAb (HuMax-Inflam); Anti-IL12 mAb (ABT-874); Anti-IL12 / IL23 mAb (CNTO 1275); Anti-IL13 mAb (CAT-354); Anti-IL2Ra mAb (HuMax-TAC); Anti-IL5 receptor mAb; Anti-integrin receptor mAb (MDX-018, CNTO 95); Anti-IP10 ulcerative colitis mAb (MDX-1100); BMS-66513; Anti-mannose receptor / hCGβ mAb (MDX-1307); Anti-mesothelin dsFv-PE38 conjugate (CAT-5001); Anti-PD1 mAb (MDX-1106(ONO-4538)); Anti-PDGFRα antibody (IMC-3G3); Anti-TGFβ mAb (GC-1008); Anti-TRAIL receptor-2 human mAb (HGS-ETR2); Anti-TWEAK mAb; Anti-VEGFR / Flt-1 mAb; and Anti-ZP3 mAb (HuMax-ZP3).

[0074] In some embodiments, the drug delivery device may include or be used with sclerosing protein antibodies, such as, but not limited to, romosozumab, blosozumab, BPS 804 (Novartis), and Evenity. TM(Lomoxozimab-aqqg), another product comprising lomoxozimab for the treatment of postmenopausal osteoporosis and / or fracture healing, and in other embodiments, comprising a monoclonal antibody (IgG) that binds to human proprotein convertase subtilisin / Kexin type 9 (PCSK9). This PCSK9-specific antibody includes, but is not limited to, […]. (evolocumab) and (alirocumab). In other embodiments, the drug delivery device may comprise or be used with rituximab, bixalomer, trebananib, ganitamumab, kanamumab, motesanib diphosphate, brodatumab, vidupiprant, or panitumumab. In some embodiments, the reservoir of the drug delivery device may be filled with [agents / medications] for the treatment of melanoma or other cancers. (Talimogene Laherparepvec) or another oncolytic HSV, or the device may be used with it, including but not limited to OncoVEX GALV / CD; OrienX010; G207; 1716; NV1020; NV12023; NV1034; and NV1042. In some embodiments, the drug delivery device may contain or be used with an endogenous tissue metalloproteinase inhibitor (TIMP), such as, but not limited to, TIMP-3. In some embodiments, the drug delivery device may contain (erenumab-aooe), anti-human CGRP-R (calcitonin gene-related peptide type 1 receptor), or another product containing erenumab for the treatment of migraine, or used in combination with it. Antagonistic antibodies against the human calcitonin gene-related peptide (CGRP) receptor (such as, but not limited to, erenumab) and bispecific antibody molecules targeting the CGRP receptor and other headache targets can also be delivered using the drug delivery device disclosed herein. Additionally, bispecific T-cell conjugates... Molecules (such as but not limited to) Blinatumomab can be used in or with the drug delivery device disclosed herein. In some embodiments, the drug delivery device may contain or be used with an APJ macromolecular agonist, such as, but not limited to, apelin or an analogue thereof. In some embodiments, a therapeutically effective amount of anti-thymic stromal lymphopoietin (TSLP) or TSLP receptor antibody is used in or with the drug delivery device disclosed herein. In some embodiments, the drug delivery device may contain Avsola for the treatment of autoimmune diseases. TM (Infliximab-axxq), anti-TNFα monoclonal antibody, (Infliximab) is a biosimilar of (Janssen Biotech, Inc.) or another product containing or used with infliximab. In some embodiments, the drug delivery device may contain [a specific ingredient] for the treatment of multiple myeloma. (Carfilzomib), (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methylepoxyethylene-2-yl)-1-oxopentane-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamyl)-4-phenylbutamido)-4-methylpentanamide, or another product containing carfilzomib or used therein. In some embodiments, the drug delivery device may contain a drug for treating various inflammatory diseases. (apremilast), N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methanesulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide, or another product containing apremilast or used therein. In some embodiments, the drug delivery device may comprise Parsabiv for treating, for example, secondary hyperparathyroidism (sHPT) in dialysis patients with chronic kidney disease (KD). TM (Vicocineptide HCl, KAI-4169) or another product containing or used with vicocineptide HCl. In some embodiments, the drug delivery device may include ABP 798 (rituximab) (a... / MabThera TMThe drug delivery device may contain or be used with a biosimilar drug candidate, or another product containing an anti-CD20 monoclonal antibody. In some embodiments, the drug delivery device may contain or be used with a VEGF antagonist (such as a non-antibody VEGF antagonist) and / or a VEGF-Trap (such as aflibercept (a fusion of the Ig domain 2 of VEGFR1 and the Ig domain 3 of VEGFR2 with the Fc domain of IgG1)). In some embodiments, the drug delivery device may contain ABP 959 (eculizumab) (a biosimilar drug candidate). The drug delivery device may comprise or be used with a biosimilar drug candidate, or another product comprising or containing a monoclonal antibody that specifically binds to complement protein C5. In some embodiments, the drug delivery device may comprise or be used with Rozibafusp alfa (formerly AMG 570), which is a novel bispecific antibody-peptide conjugate that simultaneously blocks the activities of ICOSL and BAFF. In some embodiments, the drug delivery device may comprise or be used with Omecamtiv mecarbil (a small molecule selective cardiac myosin activator), or myotrope that directly targets the cardiac contraction mechanism, or another product comprising or being used with a small molecule selective cardiac myosin activator. In some embodiments, the drug delivery device may comprise Sotorasib (formerly AMG 510) (a KRAS... G12C Small molecule inhibitors or those containing KRAS G12C Another product containing or used with small molecule inhibitors. In some embodiments, the drug delivery device may contain tezepelumab (a human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP)), or another product containing or used with a human monoclonal antibody that inhibits the action of TSLP. In some embodiments, the drug delivery device may contain AMG 714 (a human monoclonal antibody that binds to interleukin-15 (IL-15)) or another product containing or used with a human monoclonal antibody that binds to interleukin-15 (IL-15). In some embodiments, the drug delivery device may contain AMG 890 (a small interfering RNA (siRNA) that lowers lipoprotein(a) (also known as Lp(a))), or another product containing or used with a small interfering RNA (siRNA) that lowers lipoprotein(a). In some embodiments, the drug delivery device may contain ABP 654 (a human IgG1κ antibody, a... The drug delivery device may include, or be used with, another product comprising a human IgG1κ antibody and / or binding to the p40 subunits of human cytokines interleukin (IL)-12 and IL-23. In some embodiments, the drug delivery device may include Amjevita. TM Or Amgevita TM (Original name ABP 501) (Monoclonal antibody against TNF human IgG1, a type of...) The drug delivery device may include, or be used with, a biosimilar drug candidate, or another product containing or containing a human monoclonal antibody against TNF human IgG1. In some embodiments, the drug delivery device may include AMG 160, or a drug containing a long-lived (HLE) anti-prostate-specific membrane antigen (PSMA) x anti-CD3. Another product or used with the (bispecific T-cell conjugate) construct. In some embodiments, the drug delivery device may contain AMG 119, or another product or used with δ-like ligand 3 (DLL3) CAR T (chimeric antigen receptor T-cell) cell therapy. In some embodiments, the drug delivery device may contain AMG 119, or another product or used with δ-like ligand 3 (DLL3) CAR T (chimeric antigen receptor T-cell) cell therapy. In some embodiments, the drug delivery device may contain AMG 133, or another product or used with a gastric inhibitory peptide receptor (GIPR) antagonist and a GLP-1R agonist. In some embodiments, the drug delivery device may contain AMG 171, or another product or used with a growth differentiation factor 15 (GDF15) analogue. In some embodiments, the drug delivery device may contain AMG 176, or another product or used with a small molecule inhibitor of myeloid leukemia 1 (MCL-1). In some embodiments, the drug delivery device may comprise AMG 199 or a construct comprising a bispecific T-cell conjugate with extended half-life (HLE). Another product or used therewith. In some embodiments, the drug delivery device may comprise or be used with AMG 256, which is designed to selectively activate the interleukin 21 (IL-21) pathway in programmed cell death-1 (PD-1) positive cells, or another product (containing anti-PD-1x IL21 mutant protein and / or IL-21 receptor agonist). In some embodiments, the drug delivery device may comprise AMG 330 or contain anti-CD33x anti-CD3 Another product or used in conjunction with the (bispecific T-cell binding agent) construct. In some embodiments, the drug delivery device may contain AMG 404, which is being investigated for the treatment of patients with solid tumors, or another product (containing a human anti-programmed cell death-1 (PD-1) monoclonal antibody) or used in conjunction with it. In some embodiments, the drug delivery device may contain AMG 427 or contain a half-life-extended (HLE) anti-fms-like tyrosine kinase 3 (FLT3) x anti-CD3. Another product or product used with the (bispecific T-cell binding agent) construct. In some embodiments, the drug delivery device may contain AMG 430 or another product containing an anti-Jagged-1 monoclonal antibody or product used with it. In some embodiments, the drug delivery device may contain AMG 506, which is being investigated for the treatment of solid tumors, or another product (containing multispecific FAP x 4-1BB-targeted) (Biologics) or used therewith. In some embodiments, the drug delivery device may contain AMG 509 or another product containing or used therewith a bivalent T-cell conjugate, and use 2+1 technology design. In some embodiments, the drug delivery device may include AMG 562 or include HLE (high-efficiency laser-assisted) CD19 x CD3. Another product or product used with the (bispecific T-cell conjugate) construct. In some embodiments, the drug delivery device may contain or be used with Efavaleukinα (formerly AMG 592) or another product containing or being used with the IL-2 mutant Fc fusion protein. In some embodiments, the drug delivery device may contain AMG 596 or a product containing CD3 x epidermal growth factor receptor vIII (EGFRvIII). Another product of (bispecific T-cell binding agent) molecules or used in conjunction with them. In some embodiments, the drug delivery device may contain AMG 673 or contain a half-life-extended (HLE) anti-CD33 x anti-CD3 Another product of the (bispecific T-cell binding agent) construct, or used therewith, may be included. In some embodiments, the drug delivery device may comprise AMG 701 or contain extended-half-life (HLE) anti-B-cell maturation antigen (BCMA) x anti-CD3. Another product of the (bispecific T-cell binding agent) construct, or used in conjunction with it. In some embodiments, the drug delivery device may contain AMG 757 or contain a long-lasting (HLE) anti-δ-like ligand 3 (DLL3) x anti-CD3. Another product of the (bispecific T-cell binding agent) construct, or used therewith. In some embodiments, the drug delivery device may comprise AMG 910 or contain 18.2x CD3 of long-lived (HLE) epithelial cell tight junction protein claudin. Another product of the (bispecific T cell conjugate) construct is used with it.

[0075] Although drug delivery devices, components, parts, subsystems, and methods have been described with reference to exemplary embodiments, they are not limited thereto. This detailed description is to be interpreted as exemplary only and does not describe every possible embodiment of this disclosure. Many alternative embodiments can be implemented using current technology or technology developed after the date of this patent application, and these embodiments still fall within the scope of the claims defining the invention disclosed herein.

[0076] Those skilled in the art will understand that various modifications, alterations, and combinations can be made to the embodiments described above without departing from the spirit and scope of the invention disclosed herein, and such modifications, alterations, and combinations can be considered to be within the scope of the inventive concept.

Claims

1. A cardboard box for storing pharmaceuticals, the cardboard box comprising: The bottom box has a bottom wall, a first side wall, a second side wall, a rear wall, and a first front wall; The lid is attached to the bottom housing and is movable between an open position and a closed position; A release tab, the release tab including a portion of one of the cover and the bottom housing and defined by a perforated line in one of the cover and the bottom housing, the release tab including a first kiss-shaped cut portion; as well as An adhesive label is attached to the release tab and to the other of the cap and the bottom housing, and selectively attaches the cap to the bottom housing. When the cover is in the closed position, the release tab is secured to one of the cover and the bottom housing via the perforation and to the other of the cover and the bottom housing via the adhesive label. When the cover is in the open position, the release tab separates from one of the cover and the bottom box along the perforation line and is secured to the other of the cover and the bottom box via the adhesive tag.

2. The cardboard box as described in claim 1, wherein, The cap includes a top wall and a front lip.

3. The cardboard box as described in claim 2, wherein, When the cover is in the closed position, the front lip is positioned within the bottom box.

4. The cardboard box as described in claim 1, wherein, The cover includes a third sidewall adjacent to the first sidewall, a fourth sidewall adjacent to the second sidewall, and a second front wall adjacent to the first front wall.

5. The paper box as described in any one of claims 1 to 4, wherein, The release tab is a push tab that removes the release tab from either the cover or the bottom housing.

6. The paper box as claimed in any one of claims 1 to 4, wherein, The release tab includes a first portion and a second portion hinged to the first portion, such that the first portion is a push tab that partially removes the release tab from either the cover or the bottom housing, and the second portion is a tear tab that removes the remainder of the release tab from either the cover or the bottom housing.

7. The carton of claim 4, further comprising at least one tab carried by the top edge of the first front wall and at least one latching feature carried by the inner surface of the second front wall, such that when the lid is in the closed position, the at least one tab engages the at least one latching feature to resist movement of the lid to the open position.

8. The cardboard box as claimed in claim 7, wherein, The at least one latching feature includes a flap that is hinged to one of the third sidewall or the fourth sidewall and fixed to the inner surface of the second front wall.

9. The paper box as claimed in any one of claims 1 to 4, wherein, The other of the lid and the bottom box includes a second kiss-shaped cut to improve the fixation between the other of the lid and the bottom box and the adhesive label, wherein the adhesive label is disposed on the first kiss-shaped cut and the second kiss-shaped cut.

10. The paper box as claimed in any one of claims 1 to 4, wherein, The cardboard box is made from a single material.

11. The paper box as claimed in any one of claims 1 to 4, wherein, The cardboard box includes a first outer surface with a first texture, and the release tab includes a second outer surface with a second texture, the first texture being different from the second texture.

12. The cardboard box as claimed in any one of claims 4, 7, or 8, wherein, The first front wall includes a cutout adjacent to its top edge, which causes the first front wall to exhibit increased flexibility relative to the second front wall.

13. The paper box as claimed in any one of claims 1 to 4, further comprising a storage cavity disposed in the bottom box body; and a drug delivery device comprising a drug agent disposed in the storage cavity.

14. A cardboard box for storing pharmaceuticals, the cardboard box comprising: The bottom box has a bottom wall, a first side wall, a second side wall, a rear wall, and a first front wall; A lid, which is attached to the bottom housing and is movable between an open position and a closed position, wherein when the lid is in the closed position, the bottom housing is closed by the lid; A release tab, the release tab including a portion of one of the cap and the front wall and defined by a perforation line in one of the cap and the first front wall, the release tab including a snout-shaped cut; and An adhesive label is attached to the release tab and to another of the cover and the bottom housing, and selectively attaches the cover to the first front wall. When the cover is in the closed position, the release tab is secured to one of the cover and the first front wall via the adhesive tag; and When the cover is in the open position, the release tab separates from one of the cover and the first front wall along the perforation line and is secured to the other of the cover and the first front wall via the adhesive tag.

15. The cardboard box as claimed in claim 14, wherein, The cap includes a top wall and a front lip.

16. The cardboard box as claimed in claim 15, wherein, When the cover is in the closed position, the front lip is positioned within the bottom box.

17. The cardboard box as claimed in claim 14, wherein, The cover includes a third sidewall adjacent to the first sidewall, a fourth sidewall adjacent to the second sidewall, and a second front wall adjacent to the first front wall.

18. The cardboard box as claimed in claim 17, wherein, The release tab is a push tab that removes the release tab from one of the cover, the first front wall, and the second front wall.

19. The paper box as claimed in any one of claims 17 to 18, wherein, The release tab includes a first portion and a second portion hinged to the first portion, such that the first portion is a push tab that partially removes the release tab from one of the cover, the first front wall, and the second front wall, and the second portion is a tear tab that removes the remainder of the release tab from one of the cover, the first front wall, and the second front wall.

20. The carton as claimed in any one of claims 17 to 18, further comprising at least one tab carried by the top edge of the first front wall and at least one latching feature carried by the inner surface of the second front wall, such that when the lid is in the closed position, the at least one tab engages the at least one latching feature to resist movement of the lid to the open position.

21. The cardboard box as claimed in claim 20, wherein, The at least one latching feature includes a flap that is hinged to one of the third sidewall or the fourth sidewall and fixed to the inner surface of the second front wall.

22. The paper box as claimed in any one of claims 17 to 18, wherein, The adhesive label includes an anti-tamper adhesive seal.

23. The cardboard box as claimed in claim 22, wherein, The adhesive label is attached to the release tab and one of the cover, the first front wall, the second front wall, and the bottom wall of the bottom housing.

24. The paper box as claimed in any one of claims 14 to 18, wherein, The release tab includes a kiss-shaped cut to improve the fixation between the release tab and the adhesive label.

25. The paper box as claimed in any one of claims 14 to 18, wherein, The cardboard box is made from a single material.

26. The paper box as claimed in any one of claims 14 to 18, wherein, The cardboard box includes a first outer surface with a first texture, and the release tab includes a second outer surface with a second texture, the first texture being different from the second texture.

27. The paper box as claimed in any one of claims 17 to 18, wherein, The first front wall includes a cutout adjacent to its top edge, which causes the first front wall to exhibit increased flexibility relative to the second front wall.

28. The paper box as claimed in any one of claims 14 to 18, further comprising a storage cavity disposed in the bottom box body; and a drug delivery device comprising a drug agent disposed in the storage cavity.

29. A cardboard box for storing pharmaceuticals, the cardboard box comprising: The bottom box has a bottom wall, a first side wall, a second side wall, a rear wall, and a first front wall; The top, movable between an open position and a closed position, includes a top wall and a second front wall adjacent to the first front wall, wherein when the top is in the closed position, the bottom housing is disposed adjacent to the top; and The release tab includes a portion of the second front wall and is defined between the bottom edge of the second front wall and a perforation line in the second front wall. The release tab includes a first snipping-shaped cutting portion. When the top is in the open and closed positions, the release tab is secured to the bottom housing via an adhesive label; and When the top is in the open position, the release tab separates from the second front wall along the perforation line.

30. The cardboard box as claimed in claim 29, wherein, The release tab is a push tab that is removed from the second front wall.

31. The cardboard box as claimed in claim 29, wherein, The release tab includes a first portion and a second portion hinged to the first portion, such that the first portion is a push tab that partially removes the release tab from the second front wall, and the second portion is a tear tab that removes the remainder of the release tab from the second front wall.

32. The carton as claimed in any one of claims 29 to 31, further comprising at least one tab carried by the top edge of the first front wall and at least one latching feature carried by the inner surface of the second front wall, such that when the top is in the closed position, the at least one tab engages the at least one latching feature to resist movement of the top toward the open position.

33. The cardboard box as claimed in claim 32, wherein, The at least one latching feature includes a flap that is hinged to either a third sidewall hinged to the top or a fourth sidewall hinged to the top and secured to the inner surface of the second front wall.

34. The paper box as claimed in any one of claims 29 to 31, wherein, The release tab is secured to the bottom housing via the adhesive label.

35. The paper box as claimed in any one of claims 29 to 31, wherein, The release tab is secured to the bottom housing by an adhesive label, which is attached to both the release tab and the bottom housing.

36. The cardboard box as claimed in claim 35, wherein, The adhesive label is attached to the release tab and the bottom wall of the bottom box.

37. The cardboard box as claimed in claim 36, wherein, The bottom wall of the bottom box includes a second kiss-shaped cut to improve the fixation between the bottom box and the adhesive label.

38. The paper box as claimed in any one of claims 29 to 31, wherein, The cardboard box includes a first outer surface with a first texture, and the release tab includes a second outer surface with a second texture, the first texture being different from the second texture.

39. The paper box as claimed in any one of claims 29 to 31, wherein, The first front wall includes a cutout adjacent to its top edge, which causes the first front wall to exhibit increased flexibility relative to the second front wall.

40. The paper box according to any one of claims 29 to 31, further comprising a storage cavity disposed in the bottom box body; and a drug delivery device comprising a drug agent disposed in the storage cavity.

Images